{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:51:42Z","timestamp":1791438702089,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.11.015","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T09:59:17Z","timestamp":1264499957000},"page":"2459-2469","source":"Crossref","is-referenced-by-count":32,"special_numbering":"P2","title":["Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct00418626","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ophelia Q.P.","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkat","family":"Sethuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Heuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Schran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.11.015_bib1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2009.11.015_bib2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","article-title":"AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells","volume":"104","author":"Verstovsek","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.11.015_bib3","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2009.11.015_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published correction appears in Cancer Cell. 2005;7:399]","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clinthera.2009.11.015_bib5","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2009.11.015_bib6","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: A secondgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.11.015_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-200868040-00005","article-title":"Nilotinib","volume":"68","author":"Plosker","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2009.11.015_bib8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl 18S","key":"10.1016\/j.clinthera.2009.11.015_bib9","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/jco.2006.24.18_suppl.3095","article-title":"Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed\/refractory Ph+ acute lymphocytic leukemia (Ph+ALL)","volume":"24","author":"Tanaka","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2009.11.015_bib10","series-title":"Blood (ASH Annual Meeting Abstracts)","first-page":"106","article-title":"Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects","author":"Kagan","year":"2005"},{"key":"10.1016\/j.clinthera.2009.11.015_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2165\/00003088-199529050-00005","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update","volume":"29","author":"Morgan","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2009.11.015_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-199937050-00004","article-title":"Effects of liver disease on pharmacokinetics. An update [published correction appears in Clin Pharmacokinet. 2000;38:491]","volume":"37","author":"Rodighiero","year":"1999","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2009.11.015_bib13","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","year":"2004","journal-title":"As amended by the 55th World Medical Assembly, Tokyo"},{"key":"10.1016\/j.clinthera.2009.11.015_bib16","series-title":"The Liver and Portal Hypertension","first-page":"50","article-title":"Surgery and portal hypertension","author":"Child","year":"1964"},{"key":"10.1016\/j.clinthera.2009.11.015_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1016\/j.clinthera.2009.11.015_bib18","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.clinthera.2009.11.015_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.11.015_bib21","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1016\/j.clinthera.2009.11.015_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002280050113","article-title":"Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid","volume":"50","author":"Ferrara","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.11.015_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/clpt.1991.27","article-title":"Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis","volume":"49","author":"Demotes-Mainard","year":"1991","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T01:23:38Z","timestamp":1590542618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809004056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":20,"alternative-id":["S0149291809004056"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}